ProCE Banner Activity

Systemic Therapy Combinations for Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials

Slideset Download
Download this slideset for expert perspectives on emerging strategies in using immune checkpoint inhibitor combinations for patients with early- and intermediate-stage hepatocellular carcinoma.

Released: November 12, 2021

Expiration: November 11, 2022

No longer available for credit.

Share

Faculty

Amit G. Singal

Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group

Faculty Disclosure

Primary Author

Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas